Therapeutic potential of ACE inhibitors for the treatment of hypertension in Type 2 diabetes

Expert Opinion on Investigational Drugs

Volumn 9, Issue 11, 2000, Pages 2601-2617

  Komers, R ^a   Komersova, K ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

ACE inhibitors; Angiotensin AT1 receptor blockers; Diabetic nephropathy; Glomerular filtration rate; Hypertension; Microalbuminuria; Myocardial infarction; Proteinuria; Type 2 diabetes mellitus

Indexed keywords

AMLODIPINE; ANGIOTENSIN; ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN I; ANGIOTENSIN RECEPTOR; ANGIOTENSIN RECEPTOR ANTAGONIST; ATENOLOL; BETA 2 ADRENERGIC RECEPTOR BLOCKING AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRADYKININ; CAPTOPRIL; DIHYDROPYRIDINE DERIVATIVE; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; EPROSARTAN; FOSINOPRIL; GLUCOSE; INSULIN; NISOLDIPINE; NITRENDIPINE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE INHIBITOR; PLACEBO; PROSTAGLANDIN; PROTEINASE; RENIN; STREPTOZOCIN; UNINDEXED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; CHEMOPROPHYLAXIS; CLINICAL PROTOCOL; CLINICAL RESEARCH; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG EFFICACY; HUMAN; HYPERTENSION; KIDNEY DISEASE; METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PROTEINURIA; RAT; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK ASSESSMENT; TREATMENT OUTCOME; TREATMENT PLANNING; VASCULAR DISEASE;

EID: 0033757084     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.9.11.2601     Document Type: Review

References (140)

1. Diabetes mellitus and associated hypertension, vascular disease and nephropathy
2. Natural history of cardiovascular and renal disease in patients with Type 2 diabetes: Effect of therapeutic interventions and risk modifications
3. Nephropathy in patients with Type 2 diabetes
4. Prevalence of hypertension in newly presenting Type 2 diabetic patients and the association with risk factors for cardiovascular and diabetic complications
5. Effect of diureticbased antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension: Systolic hypertension in the elderly program cooperative research group
6. UK prospective diabetes study 23: Risk factors for coronary artery disease in non-insulin dependent diabetes
7. Diabetes, other risk factors and 12-yr cardiovascular mortality for men screened in the multiple risk factor intervention trial
8. A prospective study of maturity-onset diabetes mellitus and risk of coronary heart disease and stroke in women
9. Cause-specific mortality in a population-based study of diabetes
10. Diabetic nephropathy in type II diabetes
11. Albuminuria and poor glycemic control predicts mortality in NIDDM
12. Renoprotection in diabetes: Genetic and non-genetic risk factors and treatment
13. Significance of the vascular reninangiotensin pathway
14. The intrarenal reninangiotensin system: A paracrine system for the local control of renal function separate from the systemic axis
15. Physiologic actions and molecular expression of the renin-angiotensin system in the diabetic rat
16. Angiotensin II Type 2 receptor inhibits cell proliferation and activates tyrosine phosphatase
17. The angiotensin II Type 2 (AT2) receptor antagonizes the growth using gene transfer
18. Role of angiotensin subtype 2 receptor in neointima formation after vascular injury
19. Effect of AT2 receptor blockade on the pathogenesis of renal fibrosis
20. Accelerated fibrosis and collagen deposition develop in the renal interstitium of angiotensin Type II receptor knock-out mouse
21. Chronic blockade of AT2-subtype receptors prevents the effect of angiotensin II on the rat vascular structure
22. The angiotensin Type II receptor tonically inhibits angiotensin-converting enzyme in AT2 null mutant mice
23. Effects of angiotensin-converting enzyme inhibitors and angiotensin II Type 1 receptor antagonists in rats with heart failure. Role of kinins and angiotensin II Type 2 receptors
24. AT2 receptor stimulation increases aortic cyclic GMP in SHRSP by a kinindependent mechanism
25. The subtype-2 (AT2) angiotensin receptor mediates renal production of nitric oxide in conscious rats
26. Role of aldosterone in the remnant kidney model in the rat
27. Mineralocorticoid excess, dietary sodium and myocardial fibrosis
28. The renin angiotensin system in diabetes mellitus
29. Hyporeninemia and hypoaldosteronism in diabetes mellitus: A physiological and therapeutic study
30. Pathological expression of renin and angiotensin II in the renal tubule after subtotal nephrectomy. Implications for the pathogenesis of the tubulointerstitial nephrosis
31. Renal reninangiotensin system in diabetes: Functional, immunohistochemical and molecular biological correlations
32. Alterations of intrarenal renin-angiotensin and nitric oxide systems in streptozotocin-induced diabetic rats
33. Diabetes-associated mesenteric vascular hypertrophy is attenuated by angiotensin-converting enzyme inhibition
34. Enhanced renal sensitivity to angiotensin actions in diabetes mellitus in the rat
35. Interactions of the kallikrein-kinin and reninangiotensin systems in experimental diabetes
36. Increased bradykinin and 'normal' angiotensin peptide levels in diabetic Sprague-Dawley and transgenic (mRen-2)27 rats
37. Reduced glomerular angiotensin II receptor density in diabetes mellitus in the rat: Time course and mechanism
38. The cardiac renin-angiotensin system in STZ-induced diabetes
39. Autonomy of the renin system in Type II diabetes: Dietary sodium and renal hemodynamic response to ACE inhibition
40. The paradox of the low-renin state in diabetic nephropathy
41. Tissuespecific nutritional regulation of angiotensinogen in adipose tissue
42. Down regulation of the renin-angiotensin system in streprozotocin-diabetic rats
43. Increased accumulation of tissue ACE in humans atherosclerotic coronary artery disease
44. Increased levels of soluble vascular cell adhesion molecule 1 are associated with risk of cardiovascular mortality in Type II diabetes mellitus: The Hoorn study
45. Role of plasma and urinary endothelin-1 in early diabetic and hypertensive nephropathy
46. Oxidized lipoproteins found in patients with NIDDM stimulate radical-induced monocyte chemoattractant protein-1 mRNA expression in cultured human endothelial cells
47. Release of platelet plasminogen activator inhibitor 1 in whole blood is increased in patients with Type II diabetes
48. Conversion of angiotensin I to angiotensin II
49. Effects of converting enzyme inhibitors on angiotensin and bradykinin peptides
50. EDRF generation and release from perfused bovine pulmonary artery and vein
51. Paracrine regulation of the renal microcirculation
52. Inhibition of rat mesangial cell mitogenesis by nitric oxide generating vasodilators
53. Nitric oxide and angiotensin II. Glomerular and tubular interaction in the rat
54. A specific B2-bradykinin receptor antagonist HOE 140 abolishes antihypertrophic effect of ramipril
55. Kinin-mediated antihypertensive effect of captopril in deoxycorticosterone acetate-salt hypertension
56. Role of kinins and nitric oxide in the effects of angiotensin converting enzyme inhibitors on neointima formation
57. Role of kinins and nitric oxide in antihypertensive effect of ramipril
58. AT1 and TxA2/PGH2 receptors maintain hypertension throughout 2K, 1C Goldblatt hypertension in the rat
59. Effect of ACE inhibitor on DOCA-salt-and aortic coarctation-induced hypertension in mice. Do kinin B2 receptors play a role?
60. Role of bradykinin in mediating vascular effects of angiotensin-converting enzyme inhibitors in humans
61. Effect of bradykinin-receptor blockade on the response to angiotensin-converting-enzyme inhibitor in normotensive and hypertensive subjects
62. Acute renal hemodynamic effects of angiotensin converting enzyme inhibitors in diabetic hyperfiltration: The role of kinins
63. Role of angiotensin II and bradykinin in experimental diabetic nephropathy. Functional and structural studies
64. Kinins or nitric oxide, or both, are involved in the antitrophic effects of angiotensin converting enzyme inhibitors on vascular hypertrophy in the rat
65. Metabolism of angiotensin-(1-7) by angiotensin-converting enzyme
66. Counterregulatory actions of angiotensin-(1-7)
67. Angiotensin-(1-7) in the spontaneously hypertensive rat
68. Angiotensin peptides in spontaneously hypertensive and normotensive Donryu rats
69. Angiotensin-(1-7) contributes to the antihypertensive effects of blockade of the renin-angiotensin system
70. Cardiovascular actions of angiotensin-(1-7)
71. Differential responses to angiotensin-(1-7) in the feline mesenteric and hindquarters vascular beds
72. Angiotensin-(1-7) potentiates hypotensive effect of bradykinin in conscious rats
73. Angiotensin-(1-7) dilates canine coronary arteries through kinins and nitric oxide
74. Antihypertensive actions of angiotensin-(1-7) in spontaneously hypertensive rats
75. Characterization of angiotensin-(1-7) in the urine of normal and essential hypertensive subjects
76. A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension
77. ACE-inhibition increases hepatic and extrahepatic sensitivity to insulin in patients with Type 2 (non-insulin-dependent) diabetes mellitus and hypertension
78. Metabolic effects of hydrochlorothiazide and enalapril during treatment of the hypertensive diabetic patients
79. Comparative effects of lisinopril and losartan on insulin sensitivity in the treatment of non diabetic hypertensive patients
80. Placebo-controlled comparison of captopril, metoprolol and hydrochlorothiazide therapy in non-insulin-dependent diabetic patients with primary hypertension
81. Comparison of the effects of nivaldipine and captopril on glucose and lipid metabolism in NIDDM patients with hypertension
82. A new trial of efficacy, tolerability and safety of angiotensin-converting enzyme inhibition in mild systemic hypertension with concomitant diseases and therapies
83. Trandolapril does not improve insulin sensitivity in patients with hypertension and Type 2 diabetes: A double-blind, placebo controlled crossover trial
84. Metabolic effects of temocapril in hypertensive patients with diabetes mellitus Type 2
85. Insulin sensitivity in normotensive subjects during angiotensin converting enzyme inhibition with fosinopril
86. Induction of insulin resistance by beta-blockade but not ACE-inhibition: Long term treatment with atenolol or trandolapril
87. Effect of captopril on glucose concentration: Possible role of augmented postprandial forearm blood flow
88. Angiotensin converting enzyme inhibitors in diabetes: Experimental and human experience
89. ACE inhibition and glucose transport in insulin-resistant muscle: Roles of bradykinin and nitric oxide
90. Modulation of the action of insulin in relation to the energy state in skeletal muscle. Possible involvement of kinins and prostaglandins
91. Evidence that nitric oxide increases glucose transport in skeletal muscle
92. Evidence for altered sensitivity of the nitric oxide/cGMP signalling cascade in insulin-resistant skeletal muscle
93. Captopril enhances insulin responsiveness of forearm muscle tissue in non-insulin-dependent diabetes melitus
94. Role of blood flow in regulating insulin-stimulated glucose uptake in humans
95. Stimulation of glycogenolysis in hepatocytes by angiotensin II may involve both calcium release and calcium influx
96. Nonpeptide angiotensin II receptor antagonists: Studies with EXP 9270 and Dup 753 IX
97. Angiotensin II increases glucose utilisation during acute hyperinsulinemia via a hemodynamic mechanism
98. Pressor dose of angiotensin II increase insulin-mediated glucose uptake in normotensive men
99. Acute effects of blood pressure elevation on insulin clearance in normotensive healthy subjects
100. Effects of losartan on insulin sensitivity in hypertensive patients
101. Effect of an angiotensin II receptor antagonist, candesartan, on insulin resistance and pressor mechanisms in essential hypertension
102. The irbesartan Type II diabetic nephropathy trial: Study design and baseline patient characteristics
103. Characteristics of 9194 patients with left ventricular hypertrophy: The LIFE study
104. The Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial of cardiovascular events in hypertension. Rationale and design
105. Tight blood pressure control and risk of macrovascular and microvascular complications in Type 2 diabetes: UKPDS 38
106. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in Type 2 diabetes: UKPDS 39
107. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension
108. Outcome results of the fosinopril versus amlodipine cardiovascular events randomized trial (FACET) in patients with hypertension and NIDDM
109. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: Principal results of the Hypertension Optimal Treatment (HOT) randomised trial
110. Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension
111. Effect of angiotensin-converting enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: The Captopril Prevention Project (CAPPPP) randomized trial
112. Effects of an angiotensin-converting-inhibitor, ramipril, on death from cardiovascular causes, myocardial infarction and stroke in high-risk patients
113. Long-term renoprotective effect of angiotensin-converting enzyme inhibition in non-insulin-dependent diabetes mellitus. A 7-year follow-up study
114. Comparison of enalapril and nifedipine in treating non-insulin dependent diabetes associated with hypertension: One year analysis
115. Captopril or conventional therapy in hypertensive Type II diabetics. Three year analysis
116. Effects of long-term enalapril treatment on persistent micro albuminuria in well controlled hypertensive and normotensive NIDDM patients
117. Renal protective effects on enalapril in hypertensive NIDDM: Role of baseline albuminuria
118. Calcium channel blockers versus other antihypertensive therapies on progression of NIDDM associated nephropathy
119. Greater reduction of urinary albumin excretion in hypertensive Type II diabetic patients with incipient nephropathy by lisinopril than by nifedipine
120. Comparison between perindopril and nifedipine in normotensive patients with incipient diabetic nephropathy
121. Effects of cilazapril and amlodipine on kidney function in hypertensive NIDDM patients
122. Long-term treatment with either enalapril or nitrendipine stabilizes albuminuria and increases glomerular filtration rate in non-insulin-dependent diabetic patients
123. Long-term effects of lisinopril and atenolol on kidney function in hypertensive NIDDM subjects with diabetic nephropathy
124. Use of enalapril to attenuate decline in renal function in normotensive, normoalbuminuric patients with Type 2 diabetes mellitus: A randomized, controlled trial
125. Effects of an ACE inhibitor/calcium antagonist combination on proteinuria in diabetic nephropathy
126. Long-term effects of ramipril and nitrendipine on albuminuria in hypertensive patients with Type II diabetes and impaired renal function
127. Long-term effects of angiotensin-converting enzyme inhibition and metabolic control in hypertensive 2 diabetic patients
128. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: Results of the HOPE study and MICRO-HOPE substudy
129. The association of microalbuminuria and mortality in non-insulin-dependent diabetes mellitus
130. Determinants of angiotensin II generation during converting enzyme inhibition
131. Progression of left ventricular dysfunction secondary to coronary artery disease, sustained neurohumoral activation and effects of ibopamine therapy during long-term therapy with angiotensin-converting enzyme inhibitor
132. Partial escape of angiotensin converting enzyme (ACE) inhibition during prolonged ACE inhibitor treatment: Does it exist and does it affect the antihypertensive response?
133. Widespread distribution of human chymase
134. Maximally recommended doses of angiotensin-converting enzyme (ACE) inhibitors do not completely prevent ACE-mediated formation of angiotensin II in chronic heart failure
135. Optimal strategies for preventing progression of renal disease: Should angiotensin converting enzyme inhibitors and angiotensin receptor blockers be used together?
136. Comparison of candersartan, enalapril and their combination in congestive heart failure. Randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. The RESOLVD pilot study investigators
137. Additive antiproteinuric effect of converting enzyme inhibitor and losartan in normotensive patients with IgA nephropathy
138. Combination ACE inhibitor and angiotensin II receptor antagonist therapy in diabetic nephropathy
139. Role of candesartan, lisinopril and their combination on blood pressure and albuminuria in hypertensive microalbuminuric diabetic subjects
140. Intensified multifactorial intervention in patients with Type 2 diabetes mellitus and microalbuminuria: The Steno Type 2 randomized study